April 2016

Extended follow-up data continue to demonstrate the efficacy and tolerability of ibrutinib in previously treated patients with chronic lymphocytic leukemia, including those with high-risk gene mutations and prognostic features.

The experimental targeted therapy entrectinib demonstrated&nbsp;a dramatic response in a patient with metastatic&nbsp;mammary analog secretory carcinoma (MASC), which is<br /> a rare form of salivary gland cancer.

The high level of efficacy observed with the combination of bortezomib, lenalidomide, and dexamethasone in the phase III SWOG S0777 study significantly changed the frontline treatment paradigm for patients with multiple myeloma.

Navesh K. Sharma, DO, PhD, discusses the addition of Yttrium-90 resin microspheres to standard frontline FOLFOX-based chemotherapy with or without bevacizumab in patients with liver metastatic colorectal cancer.

By working together, the potential for clinical benefit in patients with cancer is increasingly bright.

With nearly a dozen new PI3K and BTK inhibitors currently in development for patients with relapsed chronic lymphocytic leukemia it is challenging to know which therapies are truly "next-generation" agents and which are "me too" products.

The breast cancer guidelines in the United States need to be fixed, which can only be accomplished by those on the frontlines. We need oncologists to chime into the discussion.